Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
Condition(s):Prostate Cancer Metastatic; Prostate CancerLast Updated:October 12, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Prostate Cancer Metastatic; Prostate CancerLast Updated:October 12, 2023Recruiting
Condition(s):Abiraterone Acetate; Gene Polymorphism; Pharmacokinetic; Metabolic Analysis; Plasma ConcentrationLast Updated:January 3, 2022Unknown status
Condition(s):Prostate CancerLast Updated:January 8, 2018Completed
Condition(s):PharmacokineticsLast Updated:March 4, 2020Completed
Condition(s):Cushing Syndrome; Adrenocortical CarcinomaLast Updated:May 10, 2017Unknown status
Condition(s):Prostate Cancer; Metastatic Cancer; Hormone Sensitive Prostate Cancer; Castration-resistant Prostate CancerLast Updated:January 8, 2024Active, not recruiting
Condition(s):Prostate Cancer MetastaticLast Updated:November 14, 2023Active, not recruiting
Condition(s):Metastatic Castration-Resistant Prostate CancerLast Updated:August 7, 2020Completed
Condition(s):Metastatic Castration Resistant Prostate CancerLast Updated:July 13, 2023Active, not recruiting
Condition(s):HealthyLast Updated:January 10, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.